Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Celecoxib in Platinum Refractory NSCLC
NCT00068653Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib, celecoxib oral solution in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jun 2003; status: completed.
02
Drugs
gefitinibcelecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00068653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068653.